Several studies have reported that obesity is a significant and independent risk factor for cardiovascular diseases. It is also associated with a wide variety of electrocardiographic abnormalities, including leftward shifts of the P wave QRS and T wave axes, various changes in P wave morphology, low QRS voltage, various markers of left ventricular hypertrophy, T wave flattening in the inferior and lateral leads, lengthening of the corrected QT (QTc) interval and prolonged QT interval duration (1). Alterations in the signal-averaged electrocardiogram (EKG) and in heart rate variability may be arrhythmogenic, and many of these EKG abnormalities are reversible with substantial weight loss (1).

QT dispersion is increased in patients with heart disease compared to healthy subjects, and prospective studies have suggested that QT dispersion has prognostic value. However, there is a great degree of overlap between healthy subjects and cardiac patients, as well as between patients with and without adverse outcome. Many investigators studied QT interval in obese patients. For instance, Bilora and coworkers reported that obese patients presented a shorter PQ, a prevalence of left cardiac axis, a higher heart rate, a longer QT, but not QTc compared with normal males; however there was no correlation between QTc and obesity (2).

In a study, newly published in this issue of the Anatolian Journal of Cardiology (3), the authors investigated the changes in QTc and QTc dispersion in obese subjects after weight loss program with diet and medical treatment. They concluded that, substantial weight loss in obese subjects was accompanied with significant decreased level of QTc dispersion, and the degree of QTc dispersion reduction was associated with amount of weight loss.

Although the results presented are impressive, we have to pay more attention to a few remarkable points. For instance, we don’t know how many patients had hypertension and left ventricular hypertrophy. It is important since, QT dispersion is increased in patients with hypertension and left ventricular hypertrophy of other causes (4-10). It is also known that correction of hypertension with regression of left ventricular hypertrophy is associated with improvement in QT dispersion (6-10). However, there is no evidence that increased QT dispersion is associated with improvement in QT dispersion. It is important since, QT dispersion is increased in patients with hypertension and left ventricular hypertrophy. It is known that coronary artery disease, a higher heart rate, a longer QT, but not QTc compared with normal males; however there was no correlation between QTc and obesity (2).

References

7. Lim PO, Nys M, Naas AA, Struthers AD, Osbakken M, MacDon-ald TM. Irbesartan reduces QT dispersion in hypertensive indi-
8. Karpanou EA, Vyssoulis GP, Psichogios A, Malakou C, Kyrozi EA, Cokkinos DV, et al. Regression of left ventricular hypertrophy re-
sults in improvement of QT dispersion in patients with hyperten-
9. Gonzalez-Juanatey JR, Garcia-Acuna JM, Pose A, Varela A, Cal-
vo C, Cabezas-Cerrato J, et al. Reduction of QT and QTc disper-
pean Society of Cardiology. The potential for QT prolongation and proarrhythmia by non-antiarrhythmic drugs: clinical and re-